Biblio
“An Exploratory Phase IIa Study of the PPAR delta/gamma Agonist T3D-959 Assessing Metabolic and Cognitive Function in Subjects with Mild to Moderate Alzheimer's Disease.”, J Alzheimers Dis, vol. 73, no. 3, pp. 1085-1103, 2020.
, “Improved Brain Insulin/IGF Signaling and Reduced Neuroinflammation with T3D-959 in an Experimental Model of Sporadic Alzheimer's Disease.”, J Alzheimers Dis, vol. 55, no. 2, pp. 849-864, 2017.
, “T3D-959: A Multi-Faceted Disease Remedial Drug Candidate for the Treatment of Alzheimer's Disease.”, J Alzheimers Dis, vol. 51, no. 1, pp. 123-38, 2016.
,